Chinese Peptide Company Ltd. announced that it will receive CNY 630,000,000 in an equity round of funding on February 29, 2016. The transaction will include participation from existing investor, Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390). On closing, the investor will retain its 100% stake in the company.

On closing, the registered capital of the company will increase from CNY 84,320,991 to CNY 714,320,991. The transaction was approved at the 11th meeting of the 6th directorate of Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390). The transaction is not subject to approval from the shareholders of Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390).